What's Going On With Pfizer Stock Thursday?
Portfolio Pulse from Dylan Berman
Pfizer shares are slightly higher after the European Commission approved Pfizer’s DURVEQTIX, a gene therapy for hemophilia B. This approval could be transformative for hemophilia B care in the EU. DURVEQTIX is already approved in the US and Canada. Analysts estimate an EPS of 46 cents and revenue of $13.02 billion for Pfizer's 2024 fiscal year second quarter.
July 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer shares are up 1.55% after the European Commission approved DURVEQTIX, a gene therapy for hemophilia B. This approval could significantly impact hemophilia B care in the EU. DURVEQTIX is already approved in the US and Canada.
The approval of DURVEQTIX by the European Commission is a significant regulatory milestone for Pfizer, potentially expanding its market in the EU. This news has already led to a 1.55% increase in Pfizer's stock price, indicating positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100